Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
NCT ID: NCT03588884
Last Updated: 2022-12-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
69 participants
INTERVENTIONAL
2018-06-08
2020-04-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CTAP101
CTAP101/Calcifediol Capsules 60 micrograms (mcg) once daily at bedtime, except on Days 1 and 29 when dosing will occur in the morning before breakfast
Calcifediol Oral Capsule
Capsule, daily
Immediate-release (IR) calcifediol
Immediate-release (IR) calcifediol/266 micrograms (mcg) capsule before breakfast on the mornings of Day 1 and Day 29
Calcifediol Oral Product
Capsule, once a month
Cholecalciferol
Cholecalciferol/Capsules 300,000 International Units (IU) (high-dose) before breakfast on the mornings of Day 1 and Day 29
Cholecalciferol
Capsule, once a month
Paricalcitol
Paricalcitol/Capsules 1 mcg plus cholecalciferol capsules 800 IU (low-dose) once daily in the morning before breakfast, except on Days 1 and29 when dosing will occur before breakfast
Cholecalciferol
Capsule, once a month
Paricalcitol Oral Capsule
Capsule, daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Calcifediol Oral Capsule
Capsule, daily
Calcifediol Oral Product
Capsule, once a month
Cholecalciferol
Capsule, once a month
Paricalcitol Oral Capsule
Capsule, daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Have stage 3 or 4 CKD (estimated glomerular filtration rate \[eGFR\] of ≥15 to \<60 millilter per minute per 1.73 meter square (mL/min/1.73 m2) using the Modification of Diet in Renal Disease equation).
3. Be without any disease state or physical condition that might impair evaluation of safety and efficacy or which, in the Investigator's opinion, would interfere with study participation, including:
1. Serum albumin ≤ 3.0 (grams per deciliter (g/dL);
2. Serum transaminase (alanine transaminase, glutamic pyruvic transaminase, aspartate aminotransferase or glutamic oxaloacetic transaminase) \> 2.5 times the upper limit of normal at screening; and,
3. Urinary albumin excretion ≤3000 microgram per milligram (μg/mg) creatinine.
4. Exhibit during the initial screening visit:
1. Plasma intact parathyroid hormone (iPTH) ≥70 picogram per milliliter (pg/mL) and \<400 pg/mL if receiving calcitriol or other 1α- hydroxylated vitamin D analog (paricalcitol or doxercalciferol); or
2. Plasma iPTH ≥100 pg/mL and \<500 pg/mL if not receiving calcitriol or other 1α- hydroxylated vitamin D analog; and,
3. Serum total 25-hydroxyvitamin D \<30 nanogram per milliliter (ng/mL).
5. If taking calcitriol, other 1α-hydroxylated vitamin D analog, or vitamin D supplementation, must forgo treatment with these non-study agents for the duration of the study and undergo a 4-week washout period.
6. Exhibit after the 4-week washout period (if required):
1. Plasma iPTH ≥100 pg/mL and \<500 pg/mL;
2. Corrected serum calcium \<9.8 mg/dL; (corrected for serum albumin)
3. Serum total 25-hydroxyvitamin D \<30 nanogram per milliliter (ng/mL); and,
4. Serum phosphorus \<5.5 milligram per deciliter (mg/dL).
7. If taking more than 1,500 milligram per day (mg/day) of elemental calcium, reduce calcium use (to approximately 1,000 to ≤1,500 mg/day) for the duration of the study.
8. Willing and able to comply with study instructions and commit to all clinic visits for the duration of the study.
9. Female subjects of childbearing potential must be neither pregnant nor lactating and must have negative blood pregnancy tests at the first screening visit.
10. All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective contraception (implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study.
11. Be able to read, understand and sign the subject Informed Consent Form (ICF) or have a legal authorized representative (LAR) sign the ICF.
Exclusion Criteria
2. History (prior 3 months) of corrected serum calcium ≥9.8 mg/dL or serum phosphorus ≥5.5 mg/dL if not receiving calcitriol or other 1α-hydroxylated vitamin D analog.
3. Need for phosphate binders to maintain the serum phosphate \< 5.5 mg/dL or use of phosphate binders within 4 weeks prior to screening
4. Use of calcimimetic therapy (cinacalcet or etelcalcetide) within 12 weeks of screening.
5. Receipt of bisphosphonate therapy or other bone modifying treatment within 6 months prior to enrollment.
6. Known previous or concomitant serious illness or medical condition, such as malignancy, human immunodeficiency virus, significant gastrointestinal or hepatic disease, intestinal malabsorption disorder, hepatitis or cardiovascular event that in the opinion of the Investigator may worsen or reduce life expectancy, and/or interfere with participation in the study.
7. History of neurological/psychiatric disorder, including psychotic disorder or dementia, or any reason which, in the opinion of the Investigator makes adherence to a treatment or follow-up schedule unlikely.
8. Known or suspected hypersensitivity to any of the constituents of the study drugs.
9. Currently participating in, or has participated in, an interventional/investigational study within 30 days prior to study screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OPKO Health, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute of Clinical Research, Inc.
Garden Grove, California, United States
Research by Design, LLC
Chicago, Illinois, United States
Spaulding Clinical Research
West Bend, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTAP101-CL-4001
Identifier Type: -
Identifier Source: org_study_id